Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 966
Filter
1.
Cornea ; 43(5): 537-544, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38305353

ABSTRACT

PURPOSE: The aim of this study was to observe the expression of interleukin (IL)-17 and intercellular adhesion molecule (ICAM)-1 in conjunctivochalasis (CCH) and to analyze the correlations between cytokines and the severity of CCH. METHODS: Serum samples were collected from 22 patients with CCH and 18 normal controls (NCs). The Ocular Surface Disease Index, tear film break-up time, Schirmer I test, and corneal fluorescein staining were used to evaluate the ocular surface signs and symptoms. The concentrations of IL-17, IL-23, and ICAM-1 in serum and cellular supernatants were measured by enzyme-linked immunosorbent assays, and the gene expression levels of cytokines were measured by a quantitative real-time polymerase chain reaction. The relationships between serum concentrations of IL-17, IL-23, and ICAM-1 with clinical ocular surface parameters in CCH were analyzed using the Spearman correlation analysis. RESULTS: The concentrations of IL-17 and ICAM-1 in serum and cellular supernatants of CCH were significantly higher than those of NCs (all P < 0.001). The concentrations of IL-23 in serum and cellular supernatants of CCH showed no significant difference from those of NCs ( P > 0.05). The mRNA expression levels of IL-17 and ICAM-1 in conjunctival fibroblasts of CCH were significantly higher than those of NCs (all P < 0.001). The mRNA expression of IL-23 in conjunctival fibroblasts of CCH was higher than that of NCs, without a significant difference ( P > 0.05). Furthermore, the serum concentrations of IL-17 and ICAM-1 were positively correlated with Ocular Surface Disease Index and fluorescein staining (all P < 0.05), and negatively correlated with break-up time and Schirmer I test of CCH (all P < 0.05). CONCLUSIONS: The expression levels of IL-17 and ICAM-1 were significantly increased in CCH serum and associated with the disease severity. We postulate that IL-17 and ICAM-1 may play a role in the pathogenesis of CCH. IL-17 and ICAM-1 antagonists may be a potential treatment option for CCH in the future.


Subject(s)
Conjunctival Diseases , Intercellular Adhesion Molecule-1 , Humans , Intercellular Adhesion Molecule-1/genetics , Interleukin-17 , Conjunctival Diseases/pathology , Cytokines , Fluorescein , Interleukin-23 , RNA, Messenger/genetics
4.
Int J Mol Sci ; 24(6)2023 Mar 17.
Article in English | MEDLINE | ID: mdl-36982810

ABSTRACT

Conjunctivochalasis is a degenerative condition of the conjunctiva that disrupts tear distribution and causes irritation. Thermoreduction of the redundant conjunctiva is required if symptoms are not relieved with medical therapy. Near-infrared laser treatment is a more controlled method to shrink the conjunctiva than thermocautery. This study compared tissue shrinkage, histology, and postoperative inflammation in thermoconjunctivoplasty performed on the mouse conjunctiva using either thermocautery or pulsed 1460 nm near-infrared laser irradiation. Three sets of experiments were performed on female C57BL/6J mice (n = 72, 26 per treatment group and 20 control) to assess conjunctival shrinkage, wound histology, and inflammation 3 and 10 days after treatment. Both treatments effectively shrunk the conjunctiva, but thermocautery caused greater epithelial damage. Thermocautery caused greater infiltration of neutrophils on day 3 and neutrophils and CD11b+ myeloid cells on day 10. The thermocautery group had significantly higher conjunctival expression of IL-1ß on day 3. Expression of chemokine CCL2 was higher in the conjunctiva on day 3 and tear concentrations were higher on day 7 in the laser group. These results suggest that pulsed laser treatment causes less tissue damage and postoperative inflammation than thermocautery while effectively addressing conjunctivochalasis.


Subject(s)
Conjunctival Diseases , Animals , Mice , Female , Mice, Inbred C57BL , Conjunctival Diseases/diagnosis , Conjunctival Diseases/pathology , Conjunctival Diseases/surgery , Conjunctiva/pathology , Cautery , Inflammation/pathology , Lasers
5.
J Fr Ophtalmol ; 46(3): 231-234, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36725373

ABSTRACT

An 18-year-old female patient was referred with complaints of tearing and redness in the left eye for 3 months after a mild ocular trauma with a turkey feather. She was treated with topical antibiotics and corticosteroids with no improvement. Slit-lamp examination of the left eye showed a vascularized lesion with a polypoidal appearance due to multiple contiguous micronodules on the temporal and inferior bulbar conjunctiva. Results of the anterior and posterior segment examination were unremarkable in both eyes. A biopsy specimen of the conjunctival mass showed multiple tuberculoid granulomas composed of epithelioid histiocytes with associated Langhan's type multinucleate giant cells and a necrotic nodule surrounded by histiocytes and giant cells. The Mantoux test was positive with induration of 15mm. The patient was prescribed antituberculosis therapy. Three months after treatment initiation, the conjunctival lesions had resolved. Mycobacterium tuberculosis should be considered in cases of unilateral chronic recalcitrant conjunctivitis. Biopsy of a conjunctival mass is of utmost importance to establish a definite diagnosis.


Subject(s)
Conjunctival Diseases , Conjunctivitis , Tuberculosis, Ocular , Female , Humans , Adolescent , Tuberculosis, Ocular/complications , Tuberculosis, Ocular/diagnosis , Tuberculosis, Ocular/drug therapy , Conjunctivitis/pathology , Granuloma/complications , Granuloma/diagnosis , Granuloma/pathology , Conjunctiva/pathology , Conjunctival Diseases/diagnosis , Conjunctival Diseases/etiology , Conjunctival Diseases/pathology
6.
Cornea ; 41(11): 1451-1454, 2022 Nov 01.
Article in English | MEDLINE | ID: mdl-36219214

ABSTRACT

PURPOSE: The purpose of this retrospective case series was to compare the outcomes of different treatment options for patients diagnosed with hereditary benign intraepithelial dyskeratosis (HBID). METHODS: The study is designed as a single-institution retrospective chart review of patients who were clinically diagnosed with HBID during their care at the Duke Eye Center. Patient demographics were obtained, and disease course after different therapies was analyzed. RESULTS: Seventeen patients were diagnosed with HBID. 52.9% (9/17) of patients identified with HBID reported Native American ancestry. Medical therapy alone failed to reduce the size or number of corneal lesions in any patient identified in this study. Ten of the 17 patients required surgical intervention. Two eyes received corneal biopsies, 3 eyes received a full conjunctival lesion excision with amniotic membrane grafting, 12 eyes received superficial keratectomy with amniotic membrane grafting, and 1 eye received keratoprosthesis. Lesion recurrence was seen in 9 of the 10 patients treated with surgical excision with an average time to recurrence of 1.5 and 2 months for conjunctival excisions and superficial keratectomy, respectively, when excluding patients who missed scheduled postoperative follow-up appointments. CONCLUSIONS: Hereditary benign intraepithelial dyskeratosis is a rare and poorly understood disorder that predominantly affects people with Native American ancestry. Medical therapy only provides symptomatic relief, and patients who receive surgical excision almost always develop recurrence. As a result, we recommend future investigations focus on identifying the optimal surgical technique and timing to limit the morbidity of HBID and improve outcomes.


Subject(s)
Conjunctival Diseases , Corneal Diseases , Conjunctival Diseases/pathology , Cornea/pathology , Corneal Diseases/genetics , Corneal Diseases/surgery , Epithelium/abnormalities , Humans , Prostheses and Implants , Retrospective Studies , Skin Abnormalities
7.
Cornea ; 41(2): 260-263, 2022 Feb 01.
Article in English | MEDLINE | ID: mdl-35037907

ABSTRACT

PURPOSE: The purpose of this article was to describe a modification to the traditional Gundersen flap technique that expands eligible eyes to include those with severe conjunctival scarring and to report results from a clinical case. METHODS: A 68-year-old woman with a history of herpes simplex keratitis, multiple failed penetrating keratoplasties, lagophthalmos, persistent epithelial defect, and low visual potential in the left eye presented for the evaluation of a Gundersen flap. Severe superior bulbar conjunctival scarring precluded a traditional approach. A modified Gundersen flap technique using a contiguous flap of inferior palpebral-bulbar conjunctiva extending from the inferior tarsal border to the limbus was devised and performed. RESULTS: The modified Gundersen flap technique successfully stabilized the ocular surface, obviating the need for a cosmetically disfiguring permanent tarsorrhaphy or an evisceration. CONCLUSIONS: This modified Gundersen flap technique expands the indications to eyes with severe conjunctival scarring and can be offered in eyes with previous trabeculectomies, glaucoma drainage implants, and scleral buckles, which were previously excluded from the globe-preserving option.


Subject(s)
Cicatrix/surgery , Conjunctiva/transplantation , Conjunctival Diseases/surgery , Ophthalmologic Surgical Procedures/methods , Postoperative Complications/surgery , Surgical Flaps , Aged , Cicatrix/etiology , Cicatrix/pathology , Conjunctival Diseases/etiology , Conjunctival Diseases/pathology , Female , Humans , Postoperative Complications/etiology , Postoperative Complications/pathology
8.
Ophthalmic Plast Reconstr Surg ; 38(3): 280-282, 2022.
Article in English | MEDLINE | ID: mdl-34750318

ABSTRACT

PURPOSE: To evaluate the clinical presentation, anatomical location, and histological features of congenital conjunctival cysts of the orbit. The location and the histological features of inflammation in these patients were compared with those for 293 orbital dermoid cysts. PATIENTS AND METHODS: Retrospective review of the clinical details, imaging, and histopathology for patients who had excision of conjunctival cysts from their orbit between 1992 and 2020; patients with a history of trauma or surgery were omitted. RESULTS: Twelve patients (7 male; 58%) with congenital conjunctival cysts were identified, the patients presenting at an average age of 16 years (median 26; range 1-61) with a symptoms for a mean duration of 20 months (median 24; range 6-36). The commonest symptoms were peribulbar lump (6/12 patients; 50%), and eyelid swelling and blepharoptosis (6/12 patients; 50%). An orbitaxl mass was palpable in 10 patients (83%), 3 patients (25%) had mild proptosis (1-3 mm), and the cysts were most commonly located superiorly (6/12 patients; 50%) or superonasally (3/12; 25%) in the anterior half of the orbit. Imaging was performed in 7 cases, this showing an intimate relation to the common sheath of the superior rectus/levator complex in 3 patients (25%) and to the trochlea in 1 (8%). All cysts were excised completely, and no patient had postoperative complications or recurrence. Chronic mild and nonspecific inflammation was evident within the cyst wall in 7 cases (54%), but-unlike 55% of the 293 dermoid cysts-none showed granuloma formation. CONCLUSION: Congenital conjunctival cysts are rare and usually present with a palpable mass in the upper eyelid sulcus. A significant proportion of these cysts have an intimate relationship with the trochlea, or the superior rectus, levator palpebrae or superior oblique muscles and, to minimize the risk of postoperative diplopia or ptosis, particular care must be exercised during surgery.


Subject(s)
Blepharoptosis , Conjunctival Diseases , Dermoid Cyst , Orbital Diseases , Blepharoptosis/pathology , Child, Preschool , Conjunctival Diseases/pathology , Dermoid Cyst/diagnosis , Dermoid Cyst/pathology , Dermoid Cyst/surgery , Humans , Infant , Inflammation , Male , Orbit/pathology , Orbital Diseases/diagnosis , Orbital Diseases/pathology , Orbital Diseases/surgery
9.
Invest Ophthalmol Vis Sci ; 62(13): 10, 2021 10 04.
Article in English | MEDLINE | ID: mdl-34643664

ABSTRACT

Purpose: The present study was designed to investigate the role of myofibroblast transdifferentiation and the conjunctival renin-angiotensin system (RAS) in the pathogenesis of graft-versus-host disease (GVHD)-associated conjunctival fibrosis. Methods: A mouse model of major histocompatibility-matched allogeneic transplantation was used to induce GVHD, with male B10.D2 mice as donors and female BALB/c mice as recipients. Male BALB/c to female BALB/c syngeneic transplantation was used as control. Y chromosome staining in the spleen cells obtained from female recipient mice was used to confirm engraftment. The phenol red thread test and fluorescein staining were used to quantify tears and corneal keratopathy. Eyes were harvested at 4 and 8 weeks after the transplant for alpha-smooth muscle actin (α-SMA), angiotensinogen, and angiotensin-converting enzyme (ACE) immunostaining. Conjunctiva was harvested for gene expression quantification of α-SMA, angiotensinogen, and ACE. Results: More than 80% of the spleen cells in the recipient mice were chromosome Y positive, thus conforming successful engraftment. A significant decrease in tear secretion and a marked increase in corneal keratopathy score after allogeneic transplantation indicated the onset of ocular GVHD in these mice. A significant increase in α-SMA gene expression and the presence of a large number of α-SMA-positive cells was noted in the bulbar orbital conjunctiva of mice after allogeneic transplantation. Allogenic transplantation also caused a significant increase in the gene expression and protein expression of angiotensinogen and ACE in the subconjunctival eyelid area. Conclusions: Results of the present study demonstrate that GVHD-associated conjunctival fibrosis is accompanied by myofibroblast formation and activation of the local conjunctival RAS.


Subject(s)
Bone Marrow Transplantation/adverse effects , Conjunctiva/pathology , Conjunctival Diseases/etiology , Graft vs Host Disease/complications , Myofibroblasts/pathology , Animals , Conjunctiva/metabolism , Conjunctival Diseases/metabolism , Conjunctival Diseases/pathology , Disease Models, Animal , Female , Fibrosis , Graft vs Host Disease/diagnosis , Male , Mice , Mice, Inbred BALB C , Myofibroblasts/metabolism
10.
Carbohydr Polym ; 269: 118341, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34294349

ABSTRACT

The rehabilitation of visual acuity with severe conjunctival fibrosis depends on ocular reconstruction with suitable conjunctival substitutes. In this study, we have developed poly(lactic acid) (PLA) electrospun nanofibrous membranes (EFMs) surface coated by cellulose nanofibrils (CNF) and/or silk peptide (SP). The CNF coating improved the hydrophilicity and the SP coating proliferated conjunctival epithelial cells (CjECs). To prevent post-operative infections, the composite scaffolds were loaded with levofloxacin (LF), constantly exerting efficient bactericidal effects. In in vivo evaluations, the PLA EFMs presented excellent therapeutic effects by promoting structural and functional restoration of conjunctiva after transplant. Even with reduced topical administration of antibiotics, the coloboma treated with LF loaded scaffolds presented no infections. It could be deduced that the potent bacterial inhibition feature could save troubles for patients by minimizing the application of antibiotics post-surgery. Hence, the developed PLA EFMs loaded with LF could be promising conjunctival substitutes.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biocompatible Materials/chemistry , Conjunctiva/drug effects , Conjunctival Diseases/therapy , Levofloxacin/pharmacology , Tissue Scaffolds/chemistry , Animals , Bacteria/drug effects , Bacterial Infections/prevention & control , Cellulose/chemistry , Conjunctiva/metabolism , Conjunctiva/pathology , Conjunctival Diseases/pathology , Drug Delivery Systems , Fibroins/chemistry , Membranes, Artificial , Nanofibers/chemistry , Polyesters/chemistry , Rabbits , Wound Healing/drug effects
12.
J Ocul Pharmacol Ther ; 37(4): 230-235, 2021 05.
Article in English | MEDLINE | ID: mdl-33684337

ABSTRACT

Purpose: In this study, we wanted to retrospectively evaluate the effect of the use of topical brimonidine on intraoperative bleeding and surgical hemostasis before strabismus surgery. Methods: Brimonidine tartrate 0.15% (Brimogut, Bilim Ilac, Turkey) eye drops were applied 6 and 3 min before surgery to 44 eyes of 22 patients in group 1 for vasoconstriction. Drops were not applied to 46 eyes of 23 patients in group 2. Preoperative and postoperative photographs and video images were taken. Black-and-white images were used to define the surface areas of the blood vessels. The surface area was calculated by counting the black pixels with ImageJ software. Results: In group 1, redness of eye was observed, on average, at preoperative 339.25 ± 11.52 pixels and intraoperative 247.93 ± 10.63 pixels (P < 0.001). But there was no change in group 2 (preoperative 338.87 ± 8.45 pixels to intraoperative 339.71 ± 9.52 pixels, P > 0.05). The incidence of intraoperative bleeding evaluated by the number of eyes on which cautery was used shows that it was significantly less in group 1 than in group 2 (P < 0.001). Conclusions: The use of topical brimonidine before strabismus surgery facilitates clear monitoring of anatomical structures during surgery by effectively controlling hemorrhage. In the postoperative period, it significantly reduces subconjunctival hemorrhage.


Subject(s)
Adrenergic alpha-2 Receptor Agonists/administration & dosage , Brimonidine Tartrate/administration & dosage , Intraoperative Complications/epidemiology , Preoperative Care/methods , Strabismus/surgery , Administration, Topical , Adolescent , Adrenergic alpha-2 Receptor Agonists/adverse effects , Adrenergic alpha-2 Receptor Agonists/pharmacology , Brimonidine Tartrate/adverse effects , Brimonidine Tartrate/pharmacology , Case-Control Studies , Child , Conjunctival Diseases/epidemiology , Conjunctival Diseases/pathology , Eye Hemorrhage/epidemiology , Eye Hemorrhage/prevention & control , Female , Hemorrhage/epidemiology , Hemorrhage/prevention & control , Hemostasis, Surgical , Humans , Hyperemia/chemically induced , Hyperemia/epidemiology , Hyperemia/prevention & control , Incidence , Male , Ophthalmic Solutions , Photography/methods , Postoperative Period , Retrospective Studies , Young Adult
15.
Sci Rep ; 10(1): 20178, 2020 11 19.
Article in English | MEDLINE | ID: mdl-33214658

ABSTRACT

To evaluate the ocular manifestation in patients hospitalized with coronavirus disease 2019 (COVID-19) and to search for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tears. This study was conducted in 29 hospitalized patients who were admitted to the COVID center at the Policlinic Hospital of the University of Messina, Italy. All patients underwent an ophthalmologic assessment comprising a Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire, anterior segment, and the ocular surface examination of both eyes using a portable slit lamp. The Schirmer I test was performed, and the filter paper strip was used to search for the presence of SARS-CoV-2 on the ocular surface by real-time quantitative polymerase chain reaction (RT-qPCR). A total of 10 patients reported ocular symptoms; in particular, four reported eye burning, three reported foreign body sensation, and three reported tearing. Moreover, seven patients presented conjunctival hyperemia and/or chemosis, eleven patients presented blepharitis signs such as lid margin hyperemia and/or telangiectasia, crusted eyelashes, and meibomian orifices alterations. Tear analysis did not reveal the presence of SARS-CoV-2. Ocular symptoms are common in patients with COVID-19; although, tear analysis did not reveal the presence of SARS-CoV-2.


Subject(s)
COVID-19/complications , Conjunctival Diseases/etiology , Corneal Diseases/etiology , Eye/pathology , Aged , Aged, 80 and over , COVID-19/pathology , Conjunctival Diseases/epidemiology , Conjunctival Diseases/pathology , Corneal Diseases/epidemiology , Corneal Diseases/pathology , Female , Humans , Male
16.
J Korean Med Sci ; 35(35): e322, 2020 Sep 07.
Article in English | MEDLINE | ID: mdl-32893523

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) has reportedly affected almost 23 million people, with more than 800 thousand deaths globally. There have been a few reports on the ocular manifestations of COVID-19 patients in China but no reports in Korea. The present study aimed to examine ocular manifestations of COVID-19 patients in Korea. METHODS: COVID-19 patients admitted from March 2020 to April 2020 at Keimyung University Dongsan Hospital and Keimyung University Daegu Dongsan Hospital were reviewed retrospectively for ocular manifestations. During the period of hospitalization, ocular symptoms as well as blood test results were noted and analyzed. Patients were then divided into the first-episode and relapsed group and ocular symptoms were analyzed in the groups. RESULTS: A total of 103 patients were included in this study. Among them, 71patients were in the first-episode group and 32 patients in the relapsed group. No significant differences were determined in terms of positivity of ocular symptoms between the first-episode group (12 patients, 16.9%) and the relapsed group (10 patients, 31.3%, P > 0.05). Symptoms of positive upper respiratory infection and lower creatine phosphokinase were determined to be related to positive ocular symptoms. Conjunctival congestion was noted in seven patients. In the subgroup analysis, the conjunctival congestion-positive patients exhibited higher positivity of upper respiratory infection symptoms (100%) as compared with those in the negative group (40%, P = 0.017). CONCLUSION: Positive upper respiratory infection symptoms and lower creatine phosphokinase were determined to be related to ocular symptoms in COVID-19 patients. Among these patients, positive upper respiratory infection symptoms were associated with conjunctival congestion.


Subject(s)
Conjunctival Diseases/pathology , Coronavirus Infections/pathology , Creatine Kinase/blood , Pneumonia, Viral/pathology , Vision Disorders/pathology , Adult , Betacoronavirus/pathogenicity , C-Reactive Protein/analysis , COVID-19 , Conjunctival Diseases/virology , Dry Eye Syndromes/pathology , Dry Eye Syndromes/virology , Female , Humans , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Pandemics , Procalcitonin/blood , Republic of Korea , Retrospective Studies , SARS-CoV-2 , Vision Disorders/virology
17.
Cornea ; 39(10): 1291-1302, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32639314

ABSTRACT

PURPOSE: In recent decades, the medical and surgical treatment of limbal stem cell deficiency (LSCD) has evolved significantly through the incorporation of innovative pharmacological strategies, surgical techniques, bioengineering, and cell therapy. With such a wide variety of options, there is a need to establish a global consensus on the preferred approaches for the medical and surgical treatment of LSCD. METHODS: An international LSCD Working Group was established by the Cornea Society in 2012 and divided into subcommittees. Four face-to-face meetings, frequent email discussions, and teleconferences were conducted since then to reach agreement on a strategic plan and methods after a comprehensive literature search. A writing group drafted the current study. RESULTS: A consensus in the medical and surgical management of LSCD was reached by the Working Group. Optimization of the ocular surface by eyelid and conjunctival reconstruction, antiinflammatory therapy, dry eye and meibomian gland dysfunction treatment, minimization of ocular surface toxicity from medications, topical medications that promote epithelialization, and use of a scleral lens is considered essential before surgical treatment of LSCD. Depending on the laterality, cause, and stage of LSCD, surgical strategies including conjunctival epitheliectomy, amniotic membrane transplantation, transplantation of limbal stem cells using different techniques and sources (allogeneic vs. autologous vs. ex vivo-cultivated), transplantation of oral mucosal epithelium, and keratoprosthesis can be performed as treatment. A stepwise flowchart for use in treatment decision-making was established. CONCLUSIONS: This global consensus provides an up-to-date and comprehensive framework for the management of LSCD.


Subject(s)
Corneal Diseases/surgery , Epithelial Cells/transplantation , Limbus Corneae/pathology , Mouth Mucosa/cytology , Stem Cell Transplantation/methods , Stem Cells/pathology , Cell Transplantation , Cells, Cultured , Conjunctival Diseases/pathology , Conjunctival Diseases/surgery , Corneal Diseases/pathology , Eyelid Diseases/pathology , Eyelid Diseases/surgery , Global Health , Humans , Transplantation, Autologous , Transplantation, Homologous , Visual Acuity/physiology
18.
Am J Case Rep ; 21: e924042, 2020 May 05.
Article in English | MEDLINE | ID: mdl-32366815

ABSTRACT

BACKGROUND Eosinophilic angiocentric fibrosis (EAF) is an extremely rare disease with characteristic histopathological findings of fibrotic onion-skin appearance and eosinophils. The lesion primarily affects the nasal cavity, paranasal sinus, and orbit. Although there have been approximately 78 cases of EAF reported in the literature to date, no cases of EAF in the eyelid conjunctiva have ever been reported. CASE REPORT Herein, we describe the case of a 55-year-old Japanese woman with a history of eosinophilic sinusitis and EAF in bilateral upper eyelid conjunctivas who underwent surgical resection of the affected tissue. Histopathological examination revealed collagen bundles winding around the vessels in an onion-skin pattern, and the presence of eosinophils, lymphocytes, and plasma cells. CONCLUSIONS We describe the first reported case of EAF in bilateral upper eyelid conjunctivas. It can be successfully treated by surgical resection, and with no recurrence within 6 months postoperatively.


Subject(s)
Conjunctiva/pathology , Conjunctival Diseases/pathology , Eosinophilia/pathology , Fibrosis/pathology , Conjunctiva/surgery , Conjunctival Diseases/surgery , Female , Fibrosis/surgery , Humans , Middle Aged
19.
J Ocul Pharmacol Ther ; 36(4): 229-233, 2020 05.
Article in English | MEDLINE | ID: mdl-32175792

ABSTRACT

Purpose: Rho-associated kinase-inhibitor ripasudil 0.4% eye drops are reportedly effective for the reduction of intraocular pressure (IOP) in glaucoma patients. However, the previous studies investigated the efficacy of IOP reduction for only about 1 year. Here, we evaluated the safety and efficacy of long-term ripasudil instillation in Japanese open-angle glaucoma (OAG) patients. Methods: This study involved 312 eyes of 312 Japanese OAG patients newly initiated with ripasudil treatment at Kyoto Prefectural University of Medicine and Oike-Ikeda Eye Clinic, Kyoto, Japan. In all patients, adverse events leading to discontinuation of ripasudil treatment were investigated. Of the 312 patients, 129 patients able to continue ripasudil administration for over 12-months post-treatment initiation were enrolled to investigate the long-term efficacy. IOP data at 0-, 1-, 3-, 6-, 12-, 18-, and 24-months post initiation of continuous ripasudil use were obtained, and the IOP values at each time point were then compared. The first period (from 1-6 months) and second period (from 12-24 months) IOP data were also compared based on the mixed model. Results: IOP at each time-point post-treatment initiation was significantly reduced compared with that at pre initiation (P < 0.05). Differences in IOP between the first and second periods of the study were not statistically significant (P = 0.058). Adverse events leading to discontinuation of treatment included blepharitis (15.7%) and conjunctival hyperemia (9.0%). Conclusions: We found that in Japanese OAG patients, 24-month ripasudil eye drop instillation is both safe and effective for lowering IOP and that blepharitis is the primary adverse event for discontinuation of use.


Subject(s)
Glaucoma, Open-Angle/drug therapy , Isoquinolines/therapeutic use , Ophthalmic Solutions/therapeutic use , Sulfonamides/therapeutic use , rho-Associated Kinases/antagonists & inhibitors , Aged , Blepharitis/chemically induced , Conjunctival Diseases/pathology , Female , Glaucoma, Open-Angle/physiopathology , Humans , Hyperemia/chemically induced , Intraocular Pressure/drug effects , Isoquinolines/administration & dosage , Isoquinolines/adverse effects , Japan/epidemiology , Male , Middle Aged , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/adverse effects , Retrospective Studies , Safety , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...